Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TisaGenlecleucel in Elderly Patients With Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma
NCT04161118Phase 2Terminated
- Sponsor
- University of Cologne
- Start
- May 2021
- Primary completion
- Feb 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisagenlecleucel in non-Hodgkin lymphoma (NHL), sponsored by University of Cologne. Primary endpoint: Complete Metabolic Response Rate at 12 weeks. Started May 2021; status: terminated.
02
Drugs
tisagenlecleucel
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04161118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04161118.